Pfizer aims to differentiate Toviaz with patient support program

Share this article:
Pfizer aims to differentiate Toviaz with patient support program
Pfizer aims to differentiate Toviaz with patient support program
Pfizer is launching Detrol follow-on Toviaz with a 12-week patient support program featuring a progress tracker, personalized emails and tips on bladder training techniques.

Patients starting on sample packs or prescriptions for the overactive bladder drug can subscribe to YourWay, a free program “developed in collaboration with experts in adherence, behavioral change and patient education and communication,” the company said.

“Patients often need additional support beyond effective medication, and physicians have limited time to provide comprehensive care,” said Sally Beatty of Pfizer communications. “This dynamic is critical because OAB is a chronic medical condition that affects about one in six Americans, yet remains under-treated.”

It's similar to support programs Pfizer offers on other brands, such as its GetQuit plan for Chantix or the MyHeartWise program for Lipitor.

Patients enrolling can choose to access the program through the website, ToviazYourWay.com, personalized weekly emails, snail mail or automated phone calls. YourWay offers tips on diet choices, bladder training techniques to help patients wait longer between bathroom breaks, information on how the drug works, and a daily progress tracker.

“Studies have shown that treatment success may be higher when behavioral therapy is used along with taking a prescription medication,” said Beatty, “yet fewer than half of OAB patients receive behavioral intervention, even from their healthcare provider.”

In addition to the program, Pfizer hopes once-daily Toviaz's flexible dosing will set it apart from predecessor Detrol LA. The new drug comes in 4 mg and 8 mg doses.

Consumer ads by McCann HumanCare will launch later in the year. Digitas is handling interactive advertising for the brand, while LyonHeart is tasked with the professional marketing assignment.
Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.